Bank of America
ESLAW icon

Bank of America’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Bank of America’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-80
Closed -$3 – 8227
2024
Q2 		$3 Buy
+80
New +$4 ﹤0.01% 8147
2023
Q3 		– Sell
-400
Closed -$16 – 7812
2023
Q2 		$16 Hold
400
– – ﹤0.01% 7527
2023
Q1 		$29 Buy
400
+100
+33% +$7 ﹤0.01% 7552
2022
Q4 		$16 Buy
+300
New +$25 ﹤0.01% 8015

Other funds holding ESLAW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America's ESLAW Position: Q3 2024 in Review

Bank of America sold out of Estrella Immunopharma Warrant (ESLAW) in Q3 2024, closing a stake of 80 shares — an estimated $3 sold.

Bank of America first reported a position in ESLAW in Q4 2022 and held it in 4 quarters. The position peaked at $29 in Q1 2023. 13 funds tracked by Wall St. Rank hold ESLAW as of Q3 2024.

  • Bank of America reported no remaining Estrella Immunopharma Warrant position as of Q3 2024 after selling out during the quarter.
  • Bank of America sold 80 Estrella Immunopharma Warrant shares in Q3 2024, an estimated $3.
  • Bank of America first reported a position in Estrella Immunopharma Warrant in Q4 2022 and held it in 4 quarters.
  • Bank of America's Estrella Immunopharma Warrant position peaked at $29 in Q1 2023.
  • 13 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q3 2024.

Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.